Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.160
0.00 (0.00%)
Apr 22, 2025, 12:18 PM EDT - Market open
Chemomab Therapeutics Employees
Chemomab Therapeutics had 20 employees as of December 31, 2021.
Employees
20
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$697,250
Market Cap
21.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
CMMB News
- 1 day ago - Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences - GlobeNewsWire
- 7 days ago - Chemomab Announces New Medical and Clinical Appointments - GlobeNewsWire
- 25 days ago - Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease - Benzinga
- 26 days ago - Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers - GlobeNewsWire
- 6 weeks ago - New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis - GlobeNewsWire
- 7 weeks ago - Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis - GlobeNewsWire
- 5 months ago - Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit - GlobeNewsWire